ISRs were one of the most frequently reported adverse events (AE) with ixekizumab. The most frequent injection site reactions observed were erythema and pain.1

ISRs were predominantly mild to moderate in severity and did not lead to discontinuation of ixekizumab.1

In the clinical trials, patients were allowed to use over-the-counter

• analgesics,
• antihistamines,
• topical antihistamines and
• topical steroids.2

Concomitant medication to treat injection site reactions (ISR) was uncommonly used. It was used in

• 1.5% of patients treated with ixekizumab every 2 weeks (Q2W) and
• 1.6% of patients treated with etanercept during the first 12 weeks of the UNCOVER studies.3

Across 7 clinical trials out of 661 patients with treatment-emergent ISR (all psoriasis ixekizumab safety population; N=4209 total patients) 

• 53 (8.0%) patients received at least one concomitant medication, and
• 608 (92.0%) patients had no concomitant ISR treatment (April 2015 data cutoff).4
  

Most patients treated for ISR received antihistamines.3

Concomitant Medications Provided for Treatment-Emergent ISRs Across 7 Psoriasis Clinical Trials summarizes the concomitant medications.

Ixekizumab is for subcutaneous injection.1

• Injection sites may be alternated.1
• The recommended places for injection of ixekizumab are the abdomen, thigh, or back of arm.4
• If possible, areas of the skin that show psoriasis should be avoided as injection sites.1

The package leaflet and the user manual give further comprehensive instructions for administration.1

The information provided is for reference only and does not constitute a treatment recommendation.

It is the decision of the prescribing health care practitioner whether to use concomitant medications in patients who experience ISRs with the use of ixekizumab.